Lina Zuo1, Yuling Chen, Wenhui Zhang. 1. Department of Respiratory Medicine, Affiliated Hospital of Xuzhou Medical College, Xuzhou 221000, China.
Abstract
OBJECTIVE: To investigate the antiviral and immuno-regulatory effects of Reduning injection on mouse cytomegalovirus (MCMV) pneumonia. METHODS: BALB/c mice were divided randomly into five groups: blank control group, immunosuppressive control group, MCMV pneumonia group, Reduning treatment group, and ganciclovir treatment group. Acute MCMV interstitial pneumonia models were established in the latter three groups. Lung pathological changes were observed with HE staining, MCMV-DNA content in the lung tissue was detected by qRT-PCR, and the levels of interferon-γ (IFN-γ) and interleukin-6 (IL-6) in the lung tissue were determined by ELISA. RESULTS: Compared with MCMV pneumonia group, the lung injuries in Reduning treatment and ganciclovir treatment groups were ameliorated, and the MCMV-DNA expression in the two treatment groups decreased, and the changes in ganciclovir treatment group were more obvious (P < 0.05). Compared with MCMV pneumonia group, the levels of IFN-γ and IL-6 in Reduning treatment group rose by 1.4 times and dropped by 30.2%, respectively; and IFN-γ increased by 1.6 times and IL-6 decreased by 47.6% in ganciclovir treatment group (P < 0.05); the differences between the two treatment groups were statistically significant (P < 0.05). IFN-γ/IL-6 ratio in Reduning treatment group was higher than that in MCMV pneumonia group, and approached the level of immunosuppressive control group. CONCLUSION: Reduning injection might exert antiviral activity through inhibiting MCMV replication and proliferation in lung tissue directly, and down-regulating the expressions of IFN-γ and IL-6.
OBJECTIVE: To investigate the antiviral and immuno-regulatory effects of Reduning injection on mouse cytomegalovirus (MCMV) pneumonia. METHODS: BALB/c mice were divided randomly into five groups: blank control group, immunosuppressive control group, MCMV pneumonia group, Reduning treatment group, and ganciclovir treatment group. Acute MCMV interstitial pneumonia models were established in the latter three groups. Lung pathological changes were observed with HE staining, MCMV-DNA content in the lung tissue was detected by qRT-PCR, and the levels of interferon-γ (IFN-γ) and interleukin-6 (IL-6) in the lung tissue were determined by ELISA. RESULTS: Compared with MCMV pneumonia group, the lung injuries in Reduning treatment and ganciclovir treatment groups were ameliorated, and the MCMV-DNA expression in the two treatment groups decreased, and the changes in ganciclovir treatment group were more obvious (P < 0.05). Compared with MCMV pneumonia group, the levels of IFN-γ and IL-6 in Reduning treatment group rose by 1.4 times and dropped by 30.2%, respectively; and IFN-γ increased by 1.6 times and IL-6 decreased by 47.6% in ganciclovir treatment group (P < 0.05); the differences between the two treatment groups were statistically significant (P < 0.05). IFN-γ/IL-6 ratio in Reduning treatment group was higher than that in MCMV pneumonia group, and approached the level of immunosuppressive control group. CONCLUSION: Reduning injection might exert antiviral activity through inhibiting MCMV replication and proliferation in lung tissue directly, and down-regulating the expressions of IFN-γ and IL-6.